Concordia Healthcare Corporation (CHEHF: OTCQX

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Concordia Healthcare Corporation (CHEHF: OTCQX International) | Concordia Healthcare Announces Successful Completion of Donnatal® Acquisition Concordia Healthcare Announces Successful Completion of Donnatal® Acquisition

Concordia Healthcare Announces Successful Completion of Donnatal® Acquisition

Canada NewsWire

TORONTO , May 15, 2014 /CNW/ - Concordia Healthcare Corp. ("Concordia" or the "Company") (TSX: CXR) (OTCQX: CHEHF), announced today that it has completed the previously announced acquisition of Donnatal ® , an adjunctive therapy in the treatment of irritable bowel syndrome ("IBS") and acute enterocolitis, from a privately held specialty pharmaceutical company carrying on business as Revive Pharmaceuticals ("Revive Pharmaceuticals").

"I am extremely pleased with this landmark achievement as it demonstrates Concordia's ability to successfully close a transaction of this magnitude, thereby opening the Company to a new level of acquisition opportunities in the future," said Mark Thompson , CEO of Concordia . "Further, the substantial anticipated revenue to be generated by Donnatal ® is expected to have a significant and positive impact on Concordia's net earnings and EBITDA."

Donnatal ® is available in two formulations: immediate release Donnatal ® Tablets, and immediate release Donnatal ® Elixir, a fast acting liquid.  For decades, Donnatal ® has delivered gentle relief from the symptoms of IBS.  In addition to the drug, Concordia is acquiring the sales and marketing infrastructure related to the product.

The International Foundation for Functional Gastrointestinal Disorders reports that irritable bowel syndrome affects between 25 and 45 million people in the United States (10 to 15 percent of the population) with a greater incidence in women.  According to the National Institutes of Health, as many as 30 percent of Americans suffer from IBS at some time in their lives. It is not associated with hospitalization and surgery, but it can severely compromise a person's quality of life.

IBS is second only to the common cold as a cause of absenteeism from work. IBS is one of the top 10 reasons for physician visits and the second most frequently encountered diagnosis in clinical practice, accounting for more physician visits than any symptoms other than those for respiratory tract infections.

"Donnatal ® is a medication that I have been prescribing for decades.  It remains an effective treatment and provides value for the management of symptoms of irritable bowel syndrome," said Dr. David A. Peura , MD, Emeritus Professor of Medicine at University of Virginia , former President and Chairman of the Board of Governors of the American Gastroenterological Association ("AGA") and recipient of the 2011 Julius Friedenwald Medal , the highest honor awarded by the AGA.

During 2013, Donnatal ® generated revenues of US$49.1 million and EBITDA 1 of US$40.2 million .

The Company acquired Donnatal ® for US$200 million in cash and an aggregate of 4,605,833 common shares of Concordia, representing approximately 16.17% of the Company's outstanding common shares on a non-diluted basis (approximately 14.96% on a fully-diluted basis) after giving effect to the acquisition.  At the closing of the acquisition, Paul Manning , founder of PBM Capital Group and Revive Pharmaceuticals, was appointed to the board of directors of the Company.

Management paid for the cash component of the acquisition through a combination of available cash and debt financing.  Accordingly, the Company entered into a secured credit facility having a principal amount of up to US$195 million , consisting of a US$170 million term loan and a US$25 million operating line (the "Credit Facility") with GE Capital, Healthcare Financial Services and a syndicate of lenders.  The Credit Facility is secured by the assets of the Company and the assets of its material subsidiaries.

Torreya Partners and GMP Securities acted as financial advisors to Concordia . Lazard Middle Market acted as financial advisor to Revive Pharmaceuticals.

About Concordia

Concordia is a diverse healthcare company focused on legacy pharmaceutical products, orphan drugs, and medical devices for the diabetic population. The Company's legacy pharmaceutical business consists of an ADHD-treatment drug, Kapvay ® (clonidine extended release tablets), Ulesfia ® (benzyl alcohol) Lotion a Head Lice Treatment, and an Asthma-related medication, Orapred ODT ® (prednisolone sodium phosphate orally disintegrating tablets). Concordia's Specialty Healthcare Distribution (SHD) division (Complete Medical Homecare) distributes medical supplies targeting diabetes and related conditions. Concordia's orphan division, Pinnacle, markets Photofrin ® in the United States .

Concordia operates out of facilities in Oakville, Ontario , Lenexa, Kansas (near Kansas City, Missouri ), Bannockburn , (near Chicago ), Illinois and Bridgetown, Barbados .

About Revive Pharmaceuticals

Charlottesville, Virginia -based Revive Pharmaceuticals is a privately held specialty pharmaceutical company that specializes in selling, distributing, marketing and manufacturing Rx products that help improve patients' health and quality of life. 

1 As used herein, "EBITDA" is defined as net income adjusted for net interest expense, income tax expense, depreciation and amortization. Management uses EBITDA to assess operating performance.

Non-IFRS Measures

This press release makes reference to certain non-IFRS measures. These non-IFRS measures are not recognized measures under IFRS and do not have a standardized meaning prescribed by IFRS, and are therefore unlikely to be comparable to similar measures presented by other companies.  When used, these measures are defined in such terms as to allow the reconciliation to the closest IFRS measure.  These measures are provided as additional information to complement those IFRS measures by providing further understanding of the Company's results of operations from management's perspective.  Accordingly, they should not be considered in isolation nor as a substitute for analyses of the Company's financial information reported under IFRS.  Management uses non-IFRS measures such as EBITDA and Adjusted EBITDA to provide investors with a supplemental measure of the Company's operating performance and thus highlight trends in the Company's core business that may not otherwise be apparent when relying solely on IFRS financial measures.  Management also believes that securities analysts, investors and other interested parties frequently use non-IFRS measures in the evaluation of issuers.  Management also uses non-IFRS measures in order to facilitate operating performance comparisons from period to period, prepare annual operating budgets, and to assess its ability to meet future debt service, capital expenditure, and working capital requirements.

Notice regarding forward-looking statements:

This release includes forward-looking statements regarding Concordia and its business, which may include, but is not limited to, statements with respect to the acquisition, the impact of the acquisition on Concordia's financial performance (including its net earnings and EBITDA), Concordia's growth and other factors.  Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "is expected", "expects", "scheduled", "intends", "contemplates", "anticipates", "believes", "proposes" or variations (including negative and grammatical variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Such statements are based on the current expectations of Concordia's management, and are based on assumptions and subject to risks and uncertainties.  Although Concordia's management believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting Concordia , including risks regarding the pharmaceutical industry, the failure to obtain regulatory approvals, economic factors, market conditions, the equity markets generally, risks associated with growth and competition, risks associated with the acquisition and many other factors beyond the control of Concordia .  Although Concordia has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Concordia undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. 

SOURCE Concordia Healthcare Corp.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

DEFSEC Tackles Nasdaq Bid Price Hurdle with Share Move

Updated Category News Views 68

Navigating Bid Price Deficiency Issues Well, it seems DEFSEC Technologies Inc. found themselves in a tricky spot last week. A nasty gram from Nasdaq’s Listing Qualifications Department pointing out that DEFSEC's shares had dipped below that $1.00 per share requirement for too long—a full 30 business days. Now, don't panic just yet. This isn't about the shares getting...

Continue Reading
Broadridge Brings Boyman In to Sharpen Its Market Story

Updated Category News Views 66

Financial plumbing rarely gets applause, which is precisely why Broadridge needs somebody who can explain its value without turning the pitch into alphabet soup. Lauren Boyman arrives as chief marketing and communications officer on November 23, taking charge of global marketing, corporate communications, product positioning, digital strategy, lead generation and thought...

Continue Reading
Frontline Claims Survey Tests AI's Real Desk Impact

Updated Category News Views 45

Claims software can look brilliant in a conference-room demo and still create a fresh pile of headaches for the person handling a real injured worker’s file. That is why the 2026 Workers’ Compensation Benchmarking Study opening its survey to frontline claims professionals matters more than the usual industry questionnaire. This is an operating-reality check, not just...

Continue Reading
1095 Days Finds the Army's Long, Ordinary War Life

Updated Category News Views 14

A cracked barracks window can explain more than a polished battlefield legend. Dean R. Cherry's 1095 Days: Three Years in the Green Machine, newly released by Palmetto Publishing, puts its weight on the parts of Army life that war stories often shove into the background: cold, waiting, paperwork, arbitrary rules, lousy living conditions, and the private mental math of...

Continue Reading
Trucking Hub Bets on Faster MVR Checks Nationwide Today

Updated Category News Views 38

Driver paperwork is where plenty of supposedly modern fleet systems still go to die. Trucking Hub’s Nov. 18 launch of GetMVR.com takes a clean swing at that mess: an online platform for ordering Motor Vehicle Records in all 50 states, with instant reports available in 48. It is not glamorous software, and frankly that is why it may matter. Fleets do not lose sleep over...

Continue Reading
LAFC Turns Empty Seats Into an AI Test Case for Sports

Updated Category News Views 180

Empty seats are a lousy kind of inventory A vacant stadium seat is perishable inventory with the clock screaming at it. LAFC and AccelerAI have aimed their first co-developed AI project at that unglamorous but important problem: getting more ticket holders through the gate without simply hacking prices down at the last minute. That is a far more sensible use of artificial...

Continue Reading
Navan’s Travel Survey Sells Friction as a Business Case

Updated Category News Views 167

A forgotten charger can turn a routine trip into a small mutiny. That is the useful little truth sitting underneath Navan’s new survey of 2,000 Americans who travel for leisure or business. The company is poking at the annoyances people carry from the bedroom packing pile to the jet bridge: forgotten items, rushed airport arrivals, pre-flight drinks, chatty strangers,...

Continue Reading
Health In Tech Brings a Tech Veteran Onto Its Board

Updated Category News Views 31

Board appointments rarely make the cash register ring, but they can tell you where management thinks the next bruises are coming from. Health In Tech has added Tim Cortes as an independent director, put him in charge of the Compensation Committee, and placed him on both the Audit and Nominating and Corporate Governance Committees. For an AI-enabled insurance technology...

Continue Reading
De Beers Puts Namibia's 176-Carat Owishi on Display

Updated Category News Views 54

A 176-carat natural diamond can still make a room stop breathing, even in a trade battered by arguments over lab-grown supply, luxury spending, and what “rare” ought to mean anymore. De Beers Group, working with Grandview Klein Diamond, has unveiled Namibia’s Owishi natural diamond in Washington, DC. That is the hard fact on the table: a large Namibian stone, a U.S....

Continue Reading
Katahdin's Portland Branch Bet Moves Downtown in 2027

Updated Category News Views 0

Exchange Street is getting a real-world vote of confidence, and that is more interesting than another app update ever will be. Katahdin Trust intends to open a full-service branch at 120 Exchange Street in downtown Portland, with renovations slated to begin early in 2027 and an opening expected later that year. For a Maine community bank with nearly $1.2 billion in...

Continue Reading

Top 5 Most Recently Viewed Articles

Cohen & Steers to Release Q2 2026 Results Soon

Updated Category News Views 30

Mark Your Calendars: July 16 Q2 2026 Results There's a buzz in the air, folks. Cohen & Steers, Inc. (NYSE: CNS) is gearing up to release its second-quarter results for 2026 on July 16, right after the market bell tolls. Now, for those in the know, the earnings release is less about the numbers dropping and more about the story they tell. On the next day, July 17, their...

Continue Reading
Legal Notice for Skye Bioscience and Perrigo Investors Amid Lawsuits

Updated Category News Views 236

Overview of Ongoing Legal Matters for Investors Bragar Eagel & Squire, P.C., a prominent law firm specializing in investor rights, wishes to inform shareholders about class action lawsuits that have been initiated against Skye Bioscience, Inc. (NASDAQ: SKYE) and Perrigo Company plc (NYSE: PRGO). These lawsuits present a vital opportunity for investors to advocate for...

Continue Reading
JD.com Shares Insights on Upcoming Financial Releases

Updated Category News Views 136

JD.com Announces Upcoming Financial Report JD.com, Inc. (NASDAQ: JD) is gearing up to release its unaudited financial results for the fourth quarter and full year of 2024. This significant announcement is scheduled for March 6, 2025, and will provide investors with a detailed look into the company's performance. Conference Call Details As part of this release, JD.com's...

Continue Reading
Marketing Maven Public Relations Celebrated for Industry Disruption

Updated Category News Views 146

Marketing Maven Public Relations and Its Notable Recognition Marketing Maven Public Relations has truly made a mark in the public relations and marketing landscape, earning recognition as a nominee for the prestigious Disruptors Awards. This accolade celebrates organizations that pioneer innovative strategies, demonstrate strategic leadership, and make impactful changes...

Continue Reading
OneMedNet Unveils Groundbreaking Platform Advancements

Updated Category News Views 132

Introduction to OneMedNet's Innovative Platform OneMedNet Corporation, a notable player in the healthcare technology field, is gearing up to showcase a groundbreaking data exploration platform at RSNA 2025. This platform, which has received enthusiastic validation from clients and industry experts, marks a significant leap in how healthcare entities manage and analyze...

Continue Reading